Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

20142,625 citationsJournal Articlebronze Open Access

Authors

Caroline Robert · Inserm

Bogusława Karaszewska

Jacob Schachter · Sheba Medical Center

Piotr Rutkowski · The Maria Sklodowska-Curie National Research Institute of Oncology

Andrzej Maćkiewicz · Poznan University of Medical Sciences

D. Stroiakovski · Moscow City Oncology Hospital №62

M. Lichinitser · Russian Cancer Research Center NN Blokhin

Abstract

Dabrafenib plus trametinib, as compared with vemurafenib monotherapy, significantly improved overall survival in previously untreated patients with metastatic melanoma with BRAF V600E or V600K mutations, without increased overall toxicity. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01597908.).

Topics & Keywords

Melanoma and MAPK Pathways Synthesis of Tetrazole Derivatives HER2/EGFR in Cancer Research

Publication Details

Published in: New England Journal of Medicine

Volume 372, Issue 1, pp. 30-39

DOI: 10.1056/nejmoa1412690

Field-Weighted Citation Impact: 120.23

Command Palette

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

Authors

Abstract

Topics & Keywords

Publication Details